A tripeptidyl ensemble perspective of interactive control of growth hormone secretion

Hormone Research

Volumn 60, Issue SUPPL. 1, 2003, Pages 86-101

  Veldhuis, Johannes D ^a,b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Gender; Ghrelin; Growth hormone; Growth hormone releasing hormone; Growth hormone releasing peptide; Insulin like growth factor I; Oestradiol; Oestrogen; Sex steroid hormones; Somatostatin; Threefold peptide control pathway; Women

Indexed keywords

GHRELIN; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HEXAPEPTIDE; HEXARELIN; HORMONE RECEPTOR STIMULATING AGENT; IBUTAMOREN; PRALMORELIN; RECOMBINANT GROWTH HORMONE; SEX HORMONE; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOSTATIN;

AGE DISTRIBUTION; CLINICAL TRIAL; CONFERENCE PAPER; GENDER; GROUPS BY AGE; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HORMONE ACTION; HORMONE INHIBITION; HUMAN; HYPOPHYSIS FUNCTION; MOLECULAR BIOLOGY; NEUROENDOCRINE SYSTEM; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SEX DIFFERENCE; SIGNAL TRANSDUCTION;

AGING; ANIMALS; APPETITE; FEEDBACK, BIOCHEMICAL; GROWTH HORMONE-RELEASING HORMONE; HUMAN GROWTH HORMONE; HUMANS; PEPTIDE HORMONES; SOMATOSTATIN;

EID: 0042413942     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000071232     Document Type: Conference Paper

References (83)

1. Giustina A, Veldhuis JD: Pathophysiology of the neuroregulation of GH secretion in experimental animals and the human. Endocr Rev 1998;19:717-797.
2. Farhi LS, Straume M, Johnson ML, Kovatchev BP, Veldhuis JD: A construct of interactive feedback control of the GH axis in the male. Am J Physiol 2001;281:R38-R51.
3. Farhy LM, Straume M, Johnson MJ, Kovatchev B, Veldhuis JD: Unequal autonegative feedback by growth hormone (GH) models the sexual dimorphism in GH secretory dynamics. Am J Physiol 2002;282:R753-R764.
4. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A: The somatomedin hypothesis: 2001. Endocr Rev 2001;22:53-74.
5. Frohman LA, Jansson J-O: Growth hormone-releasing hormone. Endocr Rev 1986;7:223-253.
6. Jaffe CA, DeMott Friberg R, Barkan AL: Suppression of growth hormone (GH) secretion by a selective GH-releasing hormone (GHRH) antagonist. J Clin Invest 1993;92:695-701.
7. Lumpkin MD, Gegro-Vilar A, McCann SM: Paradoxical elevation of growth hormone by intraventricular somatostatin: possible ultra-short-loop feedback. Science 1981;211:1072-1074.
8. Murakami Y, Kato Y, Kabayama Y, Inoue T, Koshiyama H, Imura H: Involvement of hypothalamic growth hormone (GH)-releasing factor in GH secretion induced by intracerebro-ventricular injection of somatostatin in rats. Endocrinology 1987;120:311-316.
9. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, Paress PS, Diaz C, Chou M, Liu KK, McKee KK, Pong SS, Chaung LY, Elbrecht A, Dashkevicz M, Heavens R, Rigby M, Sirinathsinghji DJS, Dean DC, Melillo DG, van der Ploeg LH: A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996;273:974-977.
10. Bowers CY, Chang J, Momany F, Folkers K: Effect of the enkephalins and enkephalin analogs on release of pituitary hormones in vitro; in MacIntyre I, Szelke M (eds): Molecular Endocrinology. Amsterdam, Elsevier Science, 1977, pp 287-292.
11. Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Ueno N, Makino S, Fujimiya M, Niijima A, Fujino MA, Kasuga M: Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 2001;120:337-345.
12. Broglio F, Arvat E, Benso A, Gottero C, Muccioli G, Papotti M, van der Lely AJ, Deghenghi R, Ghigo E: Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 2001;86:5083-5086.
13. Gianotti L, Maccario M, Lanfranco F, Ramunni J, Di Vito L, Grottoli S, Mueller EE, Ghigo E, Arvat E: Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans. J Clin Endocrinol Metab 2000;85:3604-3608.
14. Mueller EE, Locatelli V, Cocchi D: Neuroendocrine control of growth hormone secretion. Physiol Rev 1999;79:511-607.
15. Aimaretti G, Corneli G, Razzore P, Bellone S, Baffoni C, Arvat E, Camanni F, Ghigo E: Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults. J Clin Endocrinol Metab 1998;83:1615-1618.
16. Bowers CY: GH releasing peptides (GHRPs); in Kostyo J, Goodman H (eds): Handbook of Physiology. New York, Oxford University Press, 1999, pp 267-297.
17. Valetto MR, Bellone J, Baffoni C, Savio P, Aimaretti G, Gianotti L, Arvat E, Camanni F, Ghigo E: Reproducibility of the growth hormone response to stimulation with growth hormone-releasing hormone plus arginine during lifespan. Eur J Endocrinol 1996;135:568-572.
18. Bowers CY, Granda-Ayala R: GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans. J Pediatr Endocrinol Metab 1996;9:261-270.
19. Vale WW, Vaughan J, Yamamoto G, Spiess J, Rivier J: Effects of synthetic human pancreatic (tumor) GH releasing factor and somatostatin, triiodothyronine and dexamethasone on GH secretion in vitro. Endocrinology 1983;112:1553-1555.
20. Mayo KE, Miller T, DeAlmeida V, Godfrey P, Zheng J, Cunha SR: Regulation of the pituitary somatotroph cell by GHRH and its receptor. Recent Prog Horm Res 2000;55:237-266.
21. Tannenbaum GS, Zhang WH, Lapointe M, Zeitler P, Beaudet A: Growth hormone-releasing hormone neurons in the arcuate nucleus express both Sst1 and Sst2 somatostatin receptor genes. Endocrinology 1998;139:1450-1453.
22. Aguila MC: Growth hormone-releasing factor increases somatostatin release and mRNA levels in the rat periventricular nucleus via nitric oxide by activation of guanylate cyclase. Proc Natl Acad Sci USA 1994;91:782-786.
23. Aguila MC: Somatostatin decreases somatostatin messenger ribonucleic acid levels in the rat periventricular nucleus. Peptides 1998;19:1573-1579.
24. Park S, Kamegai J, Johnson TA, Frohman LA, Kineman RD: Modulation of pituitary somatostatin receptor subtype (sst1-5) messenger ribonucleic acid levels by changes in the growth hormone axis. Endocrinology 2000;141:3556-3563.
25. Baumbach WR, Carrick TA, Pausch MH, Bingham B, Carmignac D, Robinson ICAF, Houghten R, Eppler CM, Price LA, Zysk JR: A linear hexapeptide somatostatin antagonist blocks somatostatin activity in vitro and influences growth hormone release in rats. Mol Pharm 1998;54:864-873.
26. Magnan E, Cataldi M, Guillaume V, Conte-Devolx B, Graziani N, Figaroli JC, Thomas F, Chihara K, Oliver C: Acute changes in growth hormone-releasing hormone secretion after injection of BIM 23014, a long acting somatostatin analog, in rams. Life Sci 1992;51:831-838.
27. Thomas GB, Cummins JT, Francis H, Sudbury AW, McCloud PI, Clarke IJ: Effect of restricted feeding on the relationship between hypophysial portal concentrations of growth hormone (GH)-releasing factor and somatostatin, and jugular concentrations of GH in ovariectomized ewes. Endocrinology 1991;128:1151-1158.
28. Veldhuis JD, Fletcher TP, Gatford KL, Egan AR, Clarke IJ: Hypophyseal-portal somatostatin (SIRF) and jugular venous growth hormone secretion in the conscious unrestrained ewe. Neuroendocrinology 2002;75:83-91.
29. Roelfsema F, Biermasz NR, Veldman RG, Veldhuis JD, Frolich M, Stokvis-Brantsma WH, Wit J-M: Growth hormone (GH) secretion in patients with an inactivating defect of the GH-releasing hormone (GHRH) receptor is pulsatile: evidence for a role for non-GHRH inputs into the generation of GH pulses. J Clin Endocrinol Metab 2000;86:2459-2464.
30. Evans WS, Anderson SM, Hull LT, Azimi PP, Bowers CY, Veldhuis JD: Continuous 24-hour intravenous infusion of recombinant human growth hormone (GH)-releasing hormone-(1,44)-amide augments pulsatile, entropic, and daily rhythmic GH secretion in post-menopausal women equally in the estrogen-withdrawn and estrogen-supplemented states. J Clin Endocrinol Metab 2001;86:700-712.
31. Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, Oikawa S: Regulation of the ghrelin gene: growth hormone-releasing hormone upregulates ghrelin mRNA in the pituitary. Endocrinology 2001;142:4154-4157.
32. Webb CB, Vance ML, Thorner MO, Perisutti G, Thominet J, River J, Valae W, Frohman LA: Plasma growth hormone responses to constant infusion of human pancreatic growth hormone releasing factor. J Clin Invest 1984;74:96-103.
33. Iranmanesh A, South S, Liem AY, Clemmons D, Thorner MO, Weltman A, Veldhuis JD: Unequal impact of age, percentage body fat, and serum testosterone concentrations on the somatotropic, IGF-I, and IGF-binding protein responses to a three-day intravenous growth-hormone-releasing-hormone (GHRH) pulsatile infusion. Eur J Endocrinol 1998;139:59-71.
34. Zimmerman D, Young WF Jr, Ebersold MJ, Scheithauer BW, Kovacs K, Horvath E, Whitaker MD, Eberhardt NL, Downs TR, Frohman LA: Congenital gigantism due to growth hormone-releasing hormone excess and pituitary hyperplasia with adenomatous transformation. J Clin Endocrinol Metab 1993;76:216-222.
35. Soya H, Suzuki M: Somatostatin rapidly restores rat growth hormone (GH) release response attenuated by prior exposure to human GH-releasing factor in vitro. Endocrinology 1993;122:2492-2498.
36. Veldhuis JD, Roemmich JN, Rogol AD: Gender and sexual maturation-dependent contrasts in the neuroregulation of growth-hormone (GH) secretion in prepubertal and late adolescent males and females. J Clin Endocrinol Metab 2000;85:2385-2394.
37. Hoyer D, Bell GI, Epelbaum J, Feniuk W, Humphrey PPA, O'Carrol AM, Patel YC, Schonbrunn A, Taylor JE, Reisine T: Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 1995;16:756-768.
38. Djordjijevic D, Zhang J, Priam M, Viollet C, Gourdji D, Kordon C, Epelbaum J: Effect of 17beta-estradiol on somatostatin receptor expression and inhibitory effects on growth hormone and prolactin release in rat pituitary cell cultures. Endocrinology 1998;139:2272-2277.
39. Zhang WH, Beaudet A, Tannenbaum GS: Sexually dimorphic expression of sst1 and sst2 somatostatin receptor subtypes in the arcuate nucleus and anterior pituitary of adult rats. J Neuroendocrinol 1999;11:129-136.
40. Stachura ME, Tyler JM, Farmer PK: Combined effects of human growth hormone (GH)-releasing factor-44 (GRF) and somatostatin (SRIF) on post-SRIF rebound release of GH and prolactin: A model for GRF-SRIF modulation of secretion. Endocrinology 1988;123:1476-1482.
41. Buscail L, Delesque N, Esteve JP, Saint-Laurent N, Prats H, Clerc P, Robberecht P, Bell GI, Liebow C, Schally AV: Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci USA 1994;91: 2315-2319.
42. Lanneau C, Bluet-Pajot MT, Zizzari P, Csaba Z, Dournaud P, Helboe L, Hoyer D, Pellegrini E, Tannenbaum GS, Epelbaum J, Gardette R: Involvement of the SST1 somatostatin receptor subtype in the intrahypothalamic neuronal network regulating growth hormone secretion: An in vitro and in vivo antisense study. Endocrinology 2000;141:967-979.
43. Hartman ML, Pincus SM, Johnson ML, Matthews DH, Faunt LM, Vance ML, Thorner MO, Veldhuis JD: Enhanced basal and disorderly growth hormone secretion distinguish acromegalic from normal pulsatile growth hormone release. J Clin Invest 1994;94:1277-1288.
44. Slama A, Videau C, Kordon C, Epelbaum J: Estradiol regulation of somatostatin receptors in the arcuate nucleus of the female rat. Neuroendocrinology 1992;56:240-245.
45. Bray MJ, Vick TM, Shah N, Anderson SM, Rice LW, Iranmanesh A, Evans WS, Veldhuis JD: Short-term estradiol replacement in post-menopausal women selectively mutes somatostatin's dosedependent inhibition of fasting growth hormone secretion. J Clin Endocrinol Metab 2001;86:3143-3149.
46. Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe M, Miyanaga F, Takaya K, Hayashi T, Inoue G, Hosoda K, Kojima M, Kangawa K, Nakao K: Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 2001;50:227-232.
47. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656-660.
48. Peino R, Baldelli R, Rodriguez-Garcia J, Rodriguez-Segade S, Kojima M, Kangawa K, Arvat E, Ghigo E, Dieguez C, Casanueva FF: Ghrelin-induced growth hormone secretion in humans. Eur J Endocrinol 2000;143:R11-R14.
49. Korbonits M, Bustin SA, Kojima M, Jordan S, Adams EF, Lowe DG, Kangawa K, Grossman AB: The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. J Clin Endocrinol Metab 2001;86:881-887.
50. Tschop M, Smiley DL, Helman ML: Ghrelin induces adiposity in rodents. Nature 2000;407:908-913.
51. Momany F, Bowers CY, Reynolds GA, Chang D, Hong A, Newland K: Conformational energy studies and in vitro and in vivo activity data on growth hormone-releasing peptides. Endocrinology 1985;114:1531-1536.
52. Arvat E, Maccario M, Di Vito L, Broglio F, Benso A, Gottero C, Papotti M, Muccioli G, Dieguez C, Casanueva FF, Deghenghi R, Camanni F, Ghigo E: Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab 2001;86:1169-1174.
53. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO: Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab 1990;70:975-982.
54. Ariyasu H, Takaya K, Tagami T, Ogawa Y, Hosoda K, Akamizu T, Suda M, Koh T, Natsui K, Toyooka S, Shirakami G, Usui T, Shimatsu A, Doi K, Hosoda H, Kojima M, Kangawa K, Nakao K: Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 2001;86:4753-4758.
55. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS: A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001;50:1714-1719.
56. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei MA, Bloom SR: Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001;86:5992.
57. Shuto Y, Shibasaki T, Otagiri A, Kuriyama H, Ohata H, Tamura H, Kamegai J, Sugihara H, Oikawa S, Wakabayashi I: Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity. J Clin Invest 2002;109:1429-1436.
58. Shah N, Evans WS, Bowers CY, Veldhuis JD: Oral estradiol administration modulates continuous intravenous growth hormone (GH)-releasing peptide-2 driven GH secretion in postmenopausal women. J Clin Endocrinol Metab 2000;85:2649-2659.
59. Anderson SM, Shah N, Patrie JT, Evans WS, Bowers CY, Veldhuis JD: Short-term estradiol supplementation augments growth hormone (GH)-secretory responsiveness to dose-varying growth hormone-releasing peptide (GHRP-2) infusions in postmenopausal women. J Clin Endocrinol Metab 2000;86:551-560.
60. Pihoker C, Kearns GL, French D, Bowers CY: Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: A phase I study in children. J Clin Endocrinol Metab 1998;83:1168-1172.
61. Bellone J, Aimaretti G, Bartolotta E, Benso L, Imbimbo BP, Lenhaerts V, Deghenghi R, Camanni F, Ghigo E: Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during puberty. J Clin Endocrinol Metab 1995;80:1090-1094.
62. Loche S, Colao A, Cappa M, Bellone J, Aimaretti G, Farello G, Faedda A, Lombardi G, Deghenghi R, Ghigo E: The growth hormone response to hexarelin in children: Reproducibility and effect of sex steroids. J Clin Endocrinol Metab 1997;82:861-864.
63. Shah N, Evans WS, Bowers CY, Veldhuis JD: Tripartite neuroendocrine activation of the human growth-hormone (GH) axis in women by continuous 24-hour GH-releasing peptide (GHRP-2) infusion: pulsatile, entropic, and nyctohemeral mechanisms. J Clin Endocrinol Metab 1999;84:2140-2150.
64. Codner E, Cassorla F, Tiulpakov AN, Mericq MV, Avila A, Pescovitz OH, Svensson J, Cerchio K, Krupa D, Gertz BJ, Murphy G: Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children. Clin Pharmacol Ther 2001;70:91-98.
65. Klinger B, Silbergeld A, Deghenghi R, Frenkel J, Laron Z: Desensitization from long-term intranasal treatment with hexarelin does not interfere with the biological effects of this growth hormone-releasing peptide in short children. Eur J Endocrinol 1996;134:716-719.
66. Rahim A, O'Neill PA, Shalet SM: Growth hormone status during long-term hexarelin therapy. J Clin Endocrinol Metab 1998;83:1644-1649.
67. Laron Z, Frenkel J, Deghenghi R, Anin S, Klinger B, Silbergeld A: Intranasal administration of the GHRP hexarelin accelerates growth in short children. Clin Endocrinol 1995;43:631-635.
68. Mericq V, Cassorla F, Salazar T, Avila A, Iniguez G, Bowers CY, Merriam GR: Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. J Clin Endocrinol Metab 1998;83:2355-2360.
69. Bowers CY, Granda-Ayala R, Parulkar A, Anand M, Baker V, Reynolds GA, Veldhuis JD: Impact of GHRP-2 infusion for 30-90 days in older men and women with decreased GH secretion. Presented at the 81st Annual Endocrine Society Meeting, June 12-15, 1999, San Diego, USA.
70. Van den Berghe G, de Zegher F, Bowers CY, Wouters P, Muller P, Soetens F, Vlasselaers D, Schetz M, Verwaest C, Lauwers P, Bouillon R: Pituitary responsiveness to growth hormone (GH) releasing hormone, GH-releasing peptide-2 and thyrotropin releasing hormone in critical illness. Clin Endocrinol 1996;45:341-351.
71. Martha Jr PM, Goorman KM, Blizzard RM, Rogol AD, Veldhuis JD: Endogenous growth hormone secretion and clearance rates in normal boys as determined by deconvolution analysis: relationship to age, pubertal status and body mass. J Clin Endocrinol Metab 1992;74:336-344.
72. Malmlof K, Bauer MK, Johansen PB, Ankersen M, Veldhuis JD: Daily low-dose GH secretagogue administration stimulates pulsatile GH secretion and elevates plasma IGF-I levels in pigs. Endocrine 2002;16:195-199.
73. De Zegher F, Devlieger H, Eggermont E, Veldhuis JD: Properties of growth hormone and prolactin hypersecretion by the human infant on the day of birth. J Clin Endocrinol Metab 1993;76:1177-1181.
74. Wright NM, Northington FJ, Miller JD, Veldhuis JD, Rogol AD: Elevated growth hormone secretory rate in premature infants: deconvolution analysis of pulsatile GH secretion in the neonate. Pediatr Res 1992;32:286-290.
75. Aguila MC, McCann SM: Stimulation of somatostatin release in vitro by synthetic human growth hormone-releasing factor by a nondopaminergic mechanism. Endocrinology 1985;117:762-765.
76. Pellegrini E, Bluet-Pajot MT, Mounier F, Bennett P, Kordon C, Epelbaum J: Central administration of a growth hormone (GH) receptor mRNA antisense increases GH pulsatility and decreases hypothalamic somatostatin expression in rats. J Neurosci 1996;16:8140-8148.
77. Kaji H, Tai S, Okimura Y, Iguchi G, Takahashi Y, Abe H, Chihara K: Cloning and characterization of the 5′-flanking region of the human growth hormone secretagogue receptor gene. J Biol Chem 1998;273:33885-33888.
78. Miki N, Ono M, Miyoshi H, Tsushima T, Shizume K: Hypothalamic growth hormone-releasing factor (GRF) participates in the negative feedback regulation of growth hormone secretion. Life Sci 1981;44:469-476.
79. Anderson SM, Wideman L, Patrie JT, Weltman A, Bowers CY, Veldhuis JD: Estradiol supplementation selectively relieves growth hormone (GH)'s autonegative feedback on GH-releasing peptide-2 (GHRP-2)-stimulated GH secretion. J Clin Endocrinol Metab 2002;86:5904-5911.
80. Richmond E, Rogol AD, Basdemir D, Veldhuis OL, Clarke W, Bowers CY, Veldhuis JD: Accelerated escape from GH autonegative feedback in midpuberty in males: Evidence for time-delimited GH-induced somatostatinergic outflow in adolescent boys. J Clin Endocrinol Metab 2002;87:3837-3844.
81. Veldhuis JD, Bidlingmaier M, Anderson SM, Wu Z, Strasburger CJ: Lowering total plasma IGF-I concentrations by way of a novel, potent and selective GH-receptor antagonist, pegvisomant (B2036-PEG), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men. J Clin Endocrinol Metab 2001;86:3304-3310.
82. Veldhuis JD, Bidlingmaier M, Anderson SM, Evans WS, Wu Z, Strasburger CJ: Impact of experimental blockade of peripheral growth-hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. J Clin Endocrinol Metab 2002;87:5737-5745.
83. Veldhuis JD, Evans WS, Bowers CY: Impact of estradiol supplementation on dual peptidyl drive of growth-hormone secretion in postmenopausal women. J Clin Endocrinol Metab 2002;87:859-866.